What will the latest ruxolitinib tablets/ruxolitinib price be in 2025?

Ruxolitinib tablets/ruxolitinib (JAKAVI) is an oral, selective JAK inhibitor, mainly used to treat certain types of blood diseases, such as polycythemia vera and myelofibrosis etc. This drug controls the progression of the disease by inhibiting the activity of JAK enzyme, thereby reducing cytokine signaling. As a targeted therapy, ruxolitinib has shown good clinical efficacy, especially in patients who have poor response to traditional treatments.

In China, the original drug of ruxolitinib is marketed as ruxolitinib phosphate tablets and has been included in the reimbursement scope of Class B medical insurance, which undoubtedly provides financial support to the majority of patients. Common drug specifications include 14 tablets of 20mg and 60 tablets of 5mg. The price of each box is about 3,000 yuan. Due to the coverage of medical insurance, the actual patient burden will be reduced, which also makes ruxolitinib one of the important choices for the treatment of related diseases.

In addition to the domestic market, ruxolitinib is also sold in overseas markets. Taking the Turkish version of the original drug as an example, the price of each box of 5mg*60 tablets may be around 4,000 yuan. The specific price may vary due to exchange rate fluctuations. This price is slightly higher than the price of domestic original drugs, but it is still within the acceptable range.

In recent years, with the increase in market demand, generic drugs of ruxolitinib have also been launched one after another, providing patients with more choices. For example, the specifications of generic drugs produced by Bangladeshi pharmaceutical factories are 5mg*50 tablets, and the price of each box may be more than 1,000 yuan. This price is significantly lower than the original drug, allowing more patients to afford related treatment costs. At the same time, the launch of generic drugs has also intensified market competition, helping to further reduce overall medical costs.

Reference materials:https://www.jakavi.com/